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Introduction
Enzyme-replacement therapy (ERT) with alglucosidase
alfa has improved the lifespan of patients with classic
infantile Pompe disease, although ERT is not effective in
a subset of patients who mount an immune response to
the exogenous enzyme. We studied the development of
antibodies in response to ERT and its effect on clinical
outcomes in 11 patients with classic infantile Pompe
disease treated with ERT since 1999 for a median of
4.2 years (range 3 months to 12 years).
Results
We determined the endogenous acid alpha-glucosidase
expression (Cross-Reactive Immunological Material, or
CRIM status) and regularly assessed antibody formation
in all 11 patients, all of whom developed antibodies. The
patients who lacked any endogenous acid alpha-glucosi-
dase production (CRIM-negative, n=3) did not develop a
substantially different antibody titer than those who pro-
duced an inactive form of the enzyme (n=8). However,
the patient’s age at the start of ERT proved to be impor-
tant: none of the four patients who started ERT before 2
months of age developed titers of more than 1:6,250.
Gross motor function and cardiac dimension improved
less in patients with high titers and in CRIM-negative
patients. The three CRIM-negative patients have died,
whereas the eight CRIM-positive patients survived.
Conclusion
Antibody formation is common. High antibody titers
and a CRIM-negative status are associated with a poorer
clinical outcome. Earlier initiation of ERT may prevent
the formation of a severe immune response.
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